Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV cohort study

Clinical Infectious Diseases

Volumn 58, Issue 2, 2014, Pages 285-294

  Drescher, Sara M ^a   Von Wyl, Viktor ^a   Yang, Wan Lin ^a   Böni, Jürg ^b   Yerly, Sabine ^c   Shah, Cyril ^b   Aubert, Vincent ^d   Klimkait, Thomas ^e   Taffé, Patrick ^f   Furrer, Hansjakob ^g   Battegay, Manuel ^h   Ambrosioni, Juan ^c   Cavassini, Matthias ^d   Bernasconi, Enos ⁱ   Vernazza, Pietro L ^j   Ledergerber, Bruno ^a   Günthard, Huldrych F ^a   Kouyos, Roger D ^a   Aubert, V ^k   Barth, J ^k   Battegay, M ^k   Bernasconi, E ^k   Boni J ^k   Bucher, H C ^k   Burton Jeangros, C ^k   Calmy, A ^k   Cavassini, M ^k   Egger, M ^k   Elzi, L ^k   Fehr, J ^k   Fellay, J ^k   Furrer, H ^k   Fux, C A ^k   Gorgievski, M ^k   Gunthard H ^k   Haerry, D ^k   Hasse, B ^k   Hirsch, H H ^k   Hosli I ^k   Kahlert, C ^k   Kaiser, L ^k   Keiser, O ^k   Klimkait, T ^k   Kovari, H ^k   Kouyos, R ^k   Ledergerber, B ^k   Martinetti, G ^k   Martinez De Tejada, B ^k   Metzner, K ^k   Muller N ^k   Nadal, D ^k   Pantaleo, G ^k   Rauch, A ^k   Regenass, S ^k   Rickenbach, M ^k   Rudin, C ^k   Schmid, P ^k   Schultze, D ^k   Schoni Affolter F ^k   Schupbach J ^k   Speck, R ^k   Staehelin, C ^k   Tarr, P ^k   Telenti, A ^k   Trkola, A ^k   Vernazza, P ^k   Weber, R ^k   Yerly, S ^k   more..

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e UNIVERSITY OF BASEL   (Switzerland)

^f UNIVERSITY OF LAUSANNE   (Switzerland)

^g UNIVERSITY OF BERN   (Switzerland)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^j CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^k NONE

more..

Author keywords

Genotypic resistance testing; Molecular epidemiology; Transmitted antiretroviral drug resistance

Indexed keywords

ANTIVIRUS AGENT;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; COHORT ANALYSIS; DEFECTIVE VIRUS; FEMALE; GENE CLUSTER; GENE MUTATION; GENE SEQUENCE; GENETIC DISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MIDDLE AGED; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; SWITZERLAND; TREATMENT RESPONSE; VIRUS TRANSMISSION;

GENOTYPIC RESISTANCE TESTING; MOLECULAR EPIDEMIOLOGY; TRANSMITTED ANTIRETROVIRAL DRUG RESISTANCE;

ADULT; ANTI-HIV AGENTS; CLUSTER ANALYSIS; COHORT STUDIES; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HOMOSEXUALITY, MALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; PHYLOGENY; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; SEQUENCE HOMOLOGY; SWITZERLAND; YOUNG ADULT;

EID: 84891817340     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit694     Document Type: Article

References (40)

1. Palmisano L, Vella S. A brief history of antiretroviral therapy of HIV infection: Success and challenges. Ann Ist Super Sanita 2011; 47:44-8
2. Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 338:853-60
3. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997; 315:1194-9
4. Wittkop L, Günthard HF, deWolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): A European multicohort study. Lancet Infect Dis 2011; 11:363-71
5. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. New Engl J Med 2002; 347:385-94
6. Frentz D, Boucher CA, van de Vijver DA. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev 2012; 14:17-27
7. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999; 354:729-33
8. Grgic I, Lepej SZ, Lunar MM, et al. The prevalence of transmitted drug resistance in newly diagnosed HIV-infected individuals in Croatia: The role of transmission clusters of men who have sex with men carrying the T215S surveillance drug resistance mutation. AIDS Res Hum Retroviruses 2013; 9:329-36
9. Gatanaga H, Ibe S, Matsuda M, et al. Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan. Antiviral Res 2007; 75:75-82
10. Yerly S, von Wyl V, Ledergerber B, et al. Transmission of HIV-1 drug resistance in Switzerland: A 10-year molecular epidemiology survey. AIDS 2007; 21:2223-9
11. Shet A, Berry L, Mohri H, et al. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1. Clin Sci 2006; 41:439-46
12. Chaix M, Descamps D, Wirden M, et al. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS 2009; 23:717-24
13. Vercauteren J, Wensing AMJ, Van de Vijver DAMC, et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009; 200:1503-8
14. Yerly S, Junier T, Gayet-Ageron A, et al. The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. AIDS 2009; 23:1415-23
15. Burns S, Cameron S, Cane P, et al. Study HIVC, Register UK. Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom UK Collaborative Group on HIV Drug Resistance, UK Collaborative. AIDS 2007; 21:1035-9
16. Hué S, Gifford RJ, Dunn D, Fernhill E, Pillay D. Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naive individuals. J Virol 2009; 83:2645-54
17. Gifford RJ, De Oliveira T, Rambaut A, et al. Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1. J Virol 2007; 81:13050-6
18. Pybus OG, Charleston MA, Gupta S, Rambaut A, Holmes EC, Harvey PH. The epidemic behavior of the hepatitis C virus. Science 2001; 292:2323-5
19. Paraskevis D, Pybus O, Magiorkinis G, et al. Tracing the HIV-1 subtype B mobility in Europe: A phylogeographic approach. Retrovirology 2009; 6:49
20. Clewley JP, Cane PA, Pillay D. HIV-1 pol gene variation is sufficient for reconstruction of transmissions in the era of antiretroviral therapy. AIDS 2004; 18:719-28
21. Brenner BG, RogerM, Routy J-P, et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007; 195:951-9
22. Schoeni-Affolter F, Ledergerber B, Rickenbach M, et al. Cohort profile: The Swiss HIV Cohort study. Intl J Epidemiol 2010; 39:1179-89
23. Von Wyl V, Yerly S, Böni J, et al. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment. Arch Intern Med 2007; 167:1782-90
24. Swiss Federal Office of Public Health. HIV/STI-Statistiken, Analysen und Trends. Positive HIV-Tests Aidsfälle. 2006
25. Taffé P, May M; Swiss HIV Cohort Study. A joint back calculation model for the imputation of the date of HIV infection in a prevalent cohort. Stat Med 2008; 27:4835-53
26. Von Wyl V, Shah C, Bu P, et al. The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland. J Infect Dis 2011; 204:1095-103
27. Kouyos RD, von Wyl V, Yerly S, et al. Molecular epidemiology reveals long-Term changes in HIV type 1 subtype B transmission in Switzerland. J Infect Dis 2010; 201:1488-97
28. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009; 4:e4724
29. Price MN, Dehal PS, Arkin AP. FastTree 2 - Approximately maximumlikelihood trees for large alignments. PLoS One 2010; 5:e9490
30. Liu K, Linder CR, Warnow T. RAxML and FastTree: Comparing two methods for large-scale maximum likelihood phylogeny estimation. PLoS One 2011; 6:e27731
31. Kouyos RD, Von Wyl V, Yerly S, et al. Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. Clin Infect Dis 2011; 52:532-9
32. Johnson VA, Calvez V, Günthard HF, et al. 2011 update of the drug resistance mutations in HIV-1. Topics Antiviral Med 2011; 19:156-64
33. Ambrosioni J, Junier T, Delhumeau C, et al. Impact of highly active antiretroviral therapy on the molecular epidemiology of newly diagnosed HIV infections. AIDS 2012; 26:2079-86
34. Rieder P, Joos B, von Wyl V, et al. HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. AIDS 2010; 24:1177-83
35. Pingen M, Nijhuis M, de Bruijn JA, Boucher CA, Wensing AM. Evolutionary pathways of transmitted drug-resistant HIV-1. J Antimicrob Chemother 2011; 66:1467-80
36. Martinez-Picado J, Martínez MA. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: A view from the clinic and ex vivo. Virus Res 2008; 134:104-23
37. Turner D, Amit S, Chalom S, et al. Emergence of an HIV-1 cluster harbouring the major protease L90M mutation among treatment-naive patients in Tel Aviv, Israel. HIV Med 2012; 13:202-6
38. Descamps D, Chaix M, Andre P, et al. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001- 2002. J Acquir Immune Defic Syndr 2005; 38:545-52
39. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402
40. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents